On Wednesday, Following Stocks were among the “Top Losers” of U.S. Stock Market: Gevo, (NASDAQ:GEVO), The E. W. Scripps Company, (NYSE:SSP), Coherus Biosciences, (NASDAQ:CHRS), Ascent Solar Technologies, (NASDAQ:ASTI)
Gevo, (NASDAQ:GEVO), with shares declined -16.92%, closed at $0.17.
The E. W. Scripps Company, (NYSE:SSP), with shares dropped -4.24%, settled at $24.15.
Coherus Biosciences, (NASDAQ:CHRS), with shares dipped -10.79%, and closed at $27.28.
Ascent Solar Technologies, (NASDAQ:ASTI), plummeted -10.71%, and closed at $1.00.
Latest NEWS regarding these Stocks are depicted underneath:
Gevo, Inc. (NASDAQ:GEVO)
Formerly on March 26, Gevo, Inc. (GEVO), declared that in the fourth quarter of 2014, the company continued to progress the commercial operation of isobutanol at Luverne under the Side-by-Side mode of production (SBS), meeting its stated milestone in December 2014 of producing greater than fifty thousand gallons of isobutanol in one month. This achievement was a result of the introduction of Gevo’s second-generation yeast biocatalyst at the plant, in addition to noteworthy process improvements learned by Gevo since switching the plant to SBS production earlier in 2014.
Gevo also continued to develop key segments of the isobutanol market, with a focus on those where renewable isobutanol performance attributes solve customer problems. Brenntag Canada began sales of isobutanol to the specialty chemical markets, while Gulf Racing Fuels began introducing isobutanol for use in off-road applications, counting sales to retail consumers through NAPA Auto Parts in North Dakota.
Gevo, Inc., a renewable chemicals and biofuels corporation, focuses primarily on the production and sale of isobutanol and related products from renewable feedstocks. Isobutanol is a four-carbon alcohol, which is used as a specialty chemical in the production of solvents, paints, and coatings or as a value-added gasoline blendstock.
The E. W. Scripps Company (NYSE:SSP)
The E. W. Scripps Company (SSP), has accomplished the merger of its broadcast assets with those of Journal Communications and the spinoff of their respective newspapers.
Scripps and Journal simultaneously spun off and merged their newspaper operations to form Journal Media Group and right away thereafter merged their broadcast operations, making Scripps one of the nation’s largest independent TV station owners.
Shareholders of Scripps class A and ordinary voting shareholders of record as of close of business on March 25, 2015, recently received a special one-time cash dividend of $1.0297 per share and .25 share in Journal Media Group for each Scripps share they owned.
The E. W. Scripps Corporation, together with its auxiliaries, operates as a media enterprise with interests in television stations, newspapers, and local and national digital media sites. It produces news and information content that informs and engages local and national communities; and operates digital sites offering local news and information, and user-generated content.
Coherus Biosciences, Inc. (NASDAQ:CHRS)
Coherus Biosciences, Inc. (CHRS), declared the pricing of its underwritten public offering of 4,137,931 shares of its ordinary stock at a price to the public of $29.00 per share. All of the shares of the ordinary stock to be sold in the offering will be offered by Coherus. In addition, Coherus has granted the underwriters a 30-day option to purchase up to an additional 620,689 shares of ordinary stock at the public offering price, less the underwriting discount.
The offering is predictable to close on or about April 7, 2015, subject to satisfaction of customary closing conditions.
Coherus Biosciences, Inc., a late-stage clinical biologics platform corporation, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline comprises of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has accomplished a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has accomplished a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia.
Ascent Solar Technologies, Inc. (NASDAQ:ASTI)
Ascent Solar Technologies, Inc. (ASTI), declared four (4) of the corporation’s EnerPlex products won Red Dot Awards for Product Design from the Essen, Germany based awards conference: the Generatr 1200, Generatr 100, Jumpr Quad and Jumpr Stack series.
Robert Meck, Vice President of Product Engineering for EnerPlex said, “We as a corporation are honored to have our products recognized by the esteemed Red Dot Organization. Red Dot is an internationally recognized symbol of innovative and quality design, and the four EnerPlex products awarded embody those standards powerfully.”
The EnerPlex Generatr™ 100 and 1200 are ultra-lightweight lithium-ion based batteries, capable of storing immense amounts of power in an extremely compact and durable frame. Weighing up to 60% less than batteries using traditional technology, the Generatrs can go farther and power more than any battery before them.
Ascent Solar Technologies, Inc., a development stage corporation, designs and manufactures photovoltaic integrated consumer electronics; and portable power applications for commercial and military users.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
